QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
TSE:FRX

Fennec Pharmaceuticals Stock Forecast, Price & News

C$5.82
+0.43 (+7.98%)
(As of 01/18/2022 02:50 PM ET)
Add
Compare
Today's Range
C$5.82
C$5.82
50-Day Range
C$5.01
C$13.25
52-Week Range
C$4.95
C$13.25
Volume
963 shs
Average Volume
569 shs
Market Capitalization
C$151.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive FRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Fennec Pharmaceuticals logo

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Headlines

Fennec Pharmaceuticals (TSE:FRX) Shares Up 3.5%
January 8, 2022 |  americanbankingnews.com
Fennec Pharmaceuticals Expects FDA Rejection for New Drug
November 29, 2021 |  finance.yahoo.com
Stocks in play: Fennec Pharmaceuticals Inc.
June 22, 2021 |  ca.finance.yahoo.com
New Strong Sell Stocks for November 19th
November 19, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
9
Year Founded
N/A

Sales & Book Value

Annual Sales
C$170 thousand
Cash Flow
C$0.97 per share
Book Value
C$0.73 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
C$151.36 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/18/2022
Next Earnings (Estimated)
3/29/2022

MarketRank

Overall MarketRank

1.58 out of 5 stars

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Fennec Pharmaceuticals (TSE:FRX) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals
or view top-rated stocks.

How has Fennec Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Fennec Pharmaceuticals' stock was trading at C$9.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FRX stock has decreased by 35.5% and is now trading at C$5.82.
View which stocks have been most impacted by COVID-19
.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Fennec Pharmaceuticals
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc. (TSE:FRX) posted its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.01.
View Fennec Pharmaceuticals' earnings history
.

What price target have analysts set for FRX?

4 brokerages have issued 12-month price targets for Fennec Pharmaceuticals' shares. Their forecasts range from C$10.00 to C$10.00. On average, they anticipate Fennec Pharmaceuticals' share price to reach C$10.00 in the next year. This suggests a possible upside of 71.8% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, CEO & Director (Age 45, Pay $430k)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 46, Pay $311.75k)
  • Ms. Shubh Goel, Chief Commercial Officer (Age 47, Pay $360k)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 67)
  • Mr. Alexander D. Smith M.S., Consultant

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), (AD), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC) and Barrick Gold (ABX).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX."

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FRX stock can currently be purchased for approximately C$5.82.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals has a market capitalization of C$151.36 million and generates C$170 thousand in revenue each year.

How many employees does Fennec Pharmaceuticals have?

Fennec Pharmaceuticals employs 9 workers across the globe.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is fennecpharma.com.

Where are Fennec Pharmaceuticals' headquarters?

Fennec Pharmaceuticals is headquartered at 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.